2,617 results on '"Musto, Pellegrino"'
Search Results
2. IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative neoplasms
3. Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience
4. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial
5. Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study
6. Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases
7. Unveiling the competitive diffusion of binary gas mixtures in polymers: The case of carbon dioxide and alkanes in nanoporous-crystalline polyphenylene oxide
8. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
9. A stable and sensitive 2D SERS sensor for bioanalytical applications
10. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial
11. Migration of plasticizers from flexible PVC: Monitoring the concentration profiles by confocal Raman microspectroscopy
12. Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus
13. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma
14. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial
15. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
16. Polydiacetylene-coated gold nanoparticles as a novel plasmonic thermosensor based on the phase transition of the outer shell
17. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
18. Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease
19. Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma
20. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
21. Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
22. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
23. Different patterns of mast cell distribution in B-cell non-Hodgkin lymphomas
24. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
25. Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event
26. The genomic analysis brings a new piece to the molecular jigsaw of idiopathic erythrocytosis
27. Indolent Lymphoproliferative T-Cell Disorders Associated With Gastrointestional Disease: Diagnostic Challenges and Outcomes
28. Combining FTIR spectroscopy and pressure-decay techniques to analyze sorption isotherms and sorption kinetics of pure gases and their mixtures in polymers: The case of CO2 and CH4 sorption in polydimethylsiloxane
29. Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel
30. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
31. Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy.
32. Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma
33. pH activated colloidal Nanospheres: A viable sensing platform for the Therapeutic Drug Monitoring of the anticancer Drug 6-Mercaptopurine
34. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
35. Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments
36. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
37. Photonic bandgap influence on the SERS effect in metal-dielectric colloidal crystals optical fiber probe
38. Towards a personalized preventive strategy of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an ad hoc Italian expert panel
39. Optical Genome Mapping as a Tool to Unveil New Molecular Findings in Hematological Patients with Complex Chromosomal Rearrangements
40. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
41. Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant
42. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
43. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
44. IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis
45. SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma
46. Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick
47. Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia
48. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
49. Towards a predictive thermodynamic description of sorption processes in polymers: The synergy between theoretical EoS models and vibrational spectroscopy
50. Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.